StockData
Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock

CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$3.01−0.37 (-10.81%)

Close on Nov 17, 2026Market cap $58.22MP/E –Yield –

Corbus Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Corbus Pharmaceuticals's total assets was $126.99M at Jun 30, 2026. For fiscal 2025 it was $168.20M, up 7.9% from the year before. Over ten years it grew 29.3% a year on average. The highest annual figure on record is $168.20M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$168.20M+7.9%
FY2024Dec 31, 2024$155.88M+451.4%
FY2023Dec 31, 2023$28.27M-57.4%
FY2022Dec 31, 2022$66.31M-38.4%
FY2021Dec 31, 2021$107.73M+5.3%
FY2020Dec 31, 2020$102.29M+108.2%
FY2019Dec 31, 2019$49.14M+4.6%
FY2018Dec 31, 2018$46.99M-29.8%
FY2017Dec 31, 2017$66.98M+274.4%
FY2016Dec 31, 2016$17.89M+38.9%
FY2015Dec 31, 2015$12.88M+95.1%
FY2014Dec 31, 2014$6.60M+2060.5%
FY2013Dec 31, 2013$305.52K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$126.99M+1.5%
Q1 FY2026Mar 31, 2026$144.48M+3.3%
Q4 FY2025Dec 31, 2025$168.20M+7.9%
Q3 FY2025Sep 30, 2025$109.51M-33.3%
Q2 FY2025Jun 30, 2025$125.09M-17.7%
Q1 FY2025Mar 31, 2025$139.93M+11.3%
Q4 FY2024Dec 31, 2024$155.88M+451.4%
Q3 FY2024Sep 30, 2024$164.17M+352.5%
Q2 FY2024Jun 30, 2024$151.98M+247.6%
Q1 FY2024Mar 31, 2024$125.74M+143.5%
Q4 FY2023Dec 31, 2023$28.27M-57.4%
Q3 FY2023Sep 30, 2023$36.28M-50.9%
Q2 FY2023Jun 30, 2023$43.72M-46.7%
Q1 FY2023Mar 31, 2023$51.65M-46.0%
Q4 FY2022Dec 31, 2022$66.31M-38.4%
Q3 FY2022Sep 30, 2022$73.83M-38.3%
Q2 FY2022Jun 30, 2022$82.07M-32.0%
Q1 FY2022Mar 31, 2022$95.68M-31.7%
Q4 FY2021Dec 31, 2021$107.73M+5.3%
Q3 FY2021Sep 30, 2021$119.57M+24.8%
Q2 FY2021Jun 30, 2021$120.61M+22.9%
Q1 FY2021Mar 31, 2021$140.15M+114.9%
Q4 FY2020Dec 31, 2020$102.29M+108.2%
Q3 FY2020Sep 30, 2020$95.84M+40.7%
Q2 FY2020Jun 30, 2020$98.12M+16.6%
Q1 FY2020Mar 31, 2020$65.20M-35.7%
Q4 FY2019Dec 31, 2019$49.14M+4.6%
Q3 FY2019Sep 30, 2019$68.13M+11.4%
Q2 FY2019Jun 30, 2019$84.12M+19.7%
Q1 FY2019Mar 31, 2019$101.39M+31.4%
Q4 FY2018Dec 31, 2018$46.99M-29.8%
Q3 FY2018Sep 30, 2018$61.18M+59.2%
Q2 FY2018Jun 30, 2018$70.29M+57.7%
Q1 FY2018Mar 31, 2018$77.14M+52.4%
Q4 FY2017Dec 31, 2017$66.98M+274.4%
Q3 FY2017Sep 30, 2017$38.42M+94.5%
Q2 FY2017Jun 30, 2017$44.56M–
Q1 FY2017Mar 31, 2017$50.61M–
Q4 FY2016Dec 31, 2016$17.89M–
Q3 FY2016Sep 30, 2016$19.76M–

More Corbus Pharmaceuticals figures

See a number that looks wrong?